Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 233

1.

A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients.

Baratelli C, Zichi C, Di Maio M, Brizzi MP, Sonetto C, Scagliotti GV, Tampellini M.

Crit Rev Oncol Hematol. 2018 Feb;122:21-29. doi: 10.1016/j.critrevonc.2017.12.010. Epub 2017 Dec 16. Review.

PMID:
29458787
2.

Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.

Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello S, Scagliotti GV, Di Nicolantonio F, Taulli R.

Oncoimmunology. 2017 Nov 27;7(3):e1398874. doi: 10.1080/2162402X.2017.1398874. eCollection 2018.

PMID:
29399399
3.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study.

Scagliotti GV, Shuster D, Orlov S, von Pawel J, Shepherd FA, Ross JS, Wang Q, Schwartz B, Akerley W.

J Thorac Oncol. 2017 Dec 27. pii: S1556-0864(17)33112-X. doi: 10.1016/j.jtho.2017.12.009. [Epub ahead of print]

PMID:
29288764
4.

Hormonal treatment and quality of life of prostate cancer patients: new evidences.

Tucci M, Leone G, Buttigliero C, Zichi C, DI Stefano RF, Pignataro D, Vignani F, Scagliotti GV, DI Maio M.

Minerva Urol Nefrol. 2017 Dec 14. doi: 10.23736/S0393-2249.17.03066-1. [Epub ahead of print]

PMID:
29241313
5.

Implementation of precision medicine in clinical trials in thoracic oncology: Which are the hurdles?

Scagliotti GV.

Cancer. 2017 Dec 15;123(24):4764-4766. doi: 10.1002/cncr.31055. Epub 2017 Nov 10. No abstract available.

PMID:
29125618
6.

Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.

Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica V, Buttigliero C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV.

J Thorac Oncol. 2018 Jan;13(1):124-133. doi: 10.1016/j.jtho.2017.09.1968. Epub 2017 Oct 24.

PMID:
29079455
7.

Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer.

Leone G, Tucci M, Buttigliero C, Zichi C, Pignataro D, Bironzo P, Vignani F, Scagliotti GV, Di Maio M.

Endocr Relat Cancer. 2018 Jan;25(1):R1-R9. doi: 10.1530/ERC-17-0355. Epub 2017 Sep 28. Review.

8.

MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression.

Baratelli C, Tampellini M, Di Maio M, Ottone A, Brizzi MP, Forti L, Alabiso I, Sonetto C, Alabiso O, Scagliotti GV.

Int J Clin Oncol. 2017 Sep 27. doi: 10.1007/s10147-017-1195-x. [Epub ahead of print]

PMID:
28956178
9.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE study investigators.

Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6. Epub 2017 Sep 12.

PMID:
28916371
10.

Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.

Marchetti A, Barberis M, Franco R, De Luca G, Pace MV, Staibano S, Volante M, Buttitta F, Guerini-Rocco E, Righi L, D'antuono T, Scagliotti GV, Pinto C, De Rosa G, Papotti M.

J Thorac Oncol. 2017 Nov;12(11):1654-1663. doi: 10.1016/j.jtho.2017.07.031. Epub 2017 Aug 14.

PMID:
28818609
11.

LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.

Scagliotti GV, Gaafar R, Nowak AK, Reck M, Tsao AS, van Meerbeeck J, Vogelzang NJ, Nakano T, von Wangenheim U, Velema D, Morsli N, Popat S.

Clin Lung Cancer. 2017 Sep;18(5):589-593. doi: 10.1016/j.cllc.2017.03.010. Epub 2017 Mar 22.

PMID:
28690011
12.

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.

Zichi C, Tucci M, Leone G, Buttigliero C, Vignani F, Pignataro D, Scagliotti GV, Di Maio M.

Biomed Res Int. 2017;2017:5618174. doi: 10.1155/2017/5618174. Epub 2017 Jun 7. Review.

13.

Scientific Advances in Thoracic Oncology 2016.

Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR.

J Thorac Oncol. 2017 Aug;12(8):1183-1209. doi: 10.1016/j.jtho.2017.05.019. Epub 2017 Jun 1. Review.

PMID:
28579481
14.

Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies.

Langer CJ, Paz-Ares LG, Wozniak AJ, Gridelli C, de Marinis F, Pujol JL, San Antonio B, Chen J, Liu J, Oton AB, Visseren-Grul C, Scagliotti GV.

Clin Lung Cancer. 2017 Sep;18(5):489-496. doi: 10.1016/j.cllc.2017.04.003. Epub 2017 Apr 12.

PMID:
28479368
15.

Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit.

Tampellini M, Di Maio M, Baratelli C, Anania L, Brizzi MP, Sonetto C, La Salvia A, Scagliotti GV.

Clin Colorectal Cancer. 2017 Dec;16(4):372-376. doi: 10.1016/j.clcc.2017.03.019. Epub 2017 Apr 8.

PMID:
28465170
16.

Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer.

Roca E, Berruti A, Sbiera S, Rapa I, Oneda E, Sperone P, Ronchi CL, Ferrari L, Grisanti S, Germano A, Zaggia B, Scagliotti GV, Fassnacht M, Volante M, Terzolo M, Papotti M.

Endocr Relat Cancer. 2017 Jul;24(7):299-307. doi: 10.1530/ERC-17-0095. Epub 2017 Apr 21.

PMID:
28432084
17.

Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.

Germano A, Rapa I, Duregon E, Votta A, Giorcelli J, Buttigliero C, Scagliotti GV, Volante M, Terzolo M, Papotti M.

Endocr Pathol. 2017 Jun;28(2):95-102. doi: 10.1007/s12022-017-9473-8.

PMID:
28271381
18.

Pros-IT CNR: an Italian prostate cancer monitoring project.

Noale M, Maggi S, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Maurizi Enrici R, Mirone V, Montironi R, Muto G, Pecoraro S, Porreca A, Ricardi U, Tubaro A, Zagonel V, Zattoni F, Crepaldi G; Pros-IT CNR study group.

Aging Clin Exp Res. 2017 Apr;29(2):165-172. doi: 10.1007/s40520-017-0735-6. Epub 2017 Feb 24.

PMID:
28236267
19.

Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.

Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV.

Lung Cancer. 2017 Feb;104:45-51. doi: 10.1016/j.lungcan.2016.12.007. Epub 2016 Dec 12.

PMID:
28212999
20.

Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer.

Buttigliero C, Tucci M, Vignani F, Scagliotti GV, Di Maio M.

Cancer Treat Rev. 2017 Mar;54:1-9. doi: 10.1016/j.ctrv.2017.01.002. Epub 2017 Jan 11. Review.

PMID:
28135623

Supplemental Content

Loading ...
Support Center